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FractureCushing's disease with prolonged exposure to high circulating levels of glucocorticoids is associated with
deterioration of the structural integrity of bone, resulting in increased skeletal fragility and fractures. The
mechanism of bone repair following successful surgical treatment is poorly understood.
A 34-year-oldman presentedwith a tibial fracture and severely low BMD, elevated AMserum cortisol, ACTH, and
24 h urinary free cortisol, which did not suppress with 2 days of high dose dexamethasone. Following
transphenoidal resection of a pituitary microadenoma, serum cortisol and ACTH normalized. A repeat DXA at
8 months post-resection showed no change in BMD, however the Trabecular Bone Score (TBS), which reported
severe deterioration of trabecular bone architecture at diagnosis, improved to normal. At that time, teriparatide
(TPTD) was given for 2 years, which resulted in a 53.9% increase in BMD with only a small improvement in TBS.
In this patient, spontaneous recovery of trabecular bone architecture was reﬂected by the early correction in TBS.
Subsequent TPTD treatment was associated with marked improvement in BMD, presumably due to enhanced
mineralization. Complete skeletal repairwas achieved by this two-stepmechanism in a very short time following
successful surgical treatment for Cushing's disease.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cushing's disease with prolonged exposure to high serum cortisol
results in muscle atrophy, skeletal fragility and failure with fracture.
There is progressive bone degradation, primarily of trabecular bone,
resulting in fractures of the vertebral bodies, and regions of bones
with high trabecular content, such as the tibial and femoralmetaphyses.
Histologically, one ﬁnds decreased trabecular volume and increased
bone resorption with an increase in osteoclast number and activity,
along with decreased bone formation and mineralization rate
(Hermus et al., 1995; Di Somma et al., 2003). The consequences of this
weakened bone are pathologic vertebral compression fractures,
subchondral bone failure occasionally with osteonecrosis of weight
bearing or stressed bone sites. At tissue level, excess cortisol has been
shown to impair osteoblastogenic differentiation, decrease osteoblast
function and increase osteoblast apoptosis, resulting in decreased
bone formation (Canalis et al., 2007). At the cellular level, excess
steroids have been shown to induce caspase-3 activation, whichry, 519 East 72nd St Suite 206,
. This is an open access article underincreases osteocyte apoptosis and therefore also increases remodeling
at the bone surface (Rochefort et al., 2010).
The progression of skeletal catabolism to fracture is generally
understood. However, the components and progression of bone repair
following successful treatment and resolution of Cushing's disease is
less well understood. This lack of understanding of bone repair during
recovery impedes the rational selection of agents and their sequence
of application to accelerate bone repair in order to rapidly reduce
fracture risk. We present the ﬁrst case of Cushing's disease induced
osteoporosis in a young male patient demonstrating spontaneous nor-
malization of trabecular bone score (TBS) 8 months after surgical cure,
followed by accelerated bone mineralization with Teriparatide (TPTD).2. Material and methods
Bone density (DXA) scans were obtained on the same Lunar Prodigy
densitometer and the anonymized scan data were sent to the University
of Lausanne, Switzerland for the calculation of spine TBS using the
medimaps TBS iNsight®-2.1 software for texture analysis. A tighter/fuller
trabecular network produces an image with many gray level variations
of small amplitudes, which translates into a steep slope and a high TBS
value (Hans et al., 2011). Blood tests were processed at the Quest lab.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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A 34-year-old man was referred to Hospital for Special Surgery for
metabolic bone disease evaluation after suffering a non-traumatic tibial
stress fracture and subsequent development of avascular necrosis of the
left femoral head.
On physical exam, he had truncal obesity with a slightly protuberant
abdomen and large purple striae. Initial labs revealed elevated AM corti-
sol (21.6 ug/dl, nl 8–19 ug/dl) and urinary free cortisol (561 ug/24 h, nl
b250 ug/24 h). After 1mgdexamethasone, AMCortisol remained elevat-
ed (27.2 ug/dl, nl b1.8 ug/dl) and ACTH did not suppress (84 pg/ml, nl
b 48 pg/ml). Patient also had increased bone resorption evidenced by
elevated NTX (65 nM BCE/mM, nl 3–51 nM BCE/mM), and had low
vitamin D 25(OH) (24.8 ng/ml, nl 30–100 ng/ml) with intact PTH
(54 pg/ml, nl 15–65 pg/ml). Bone formation markers such as P1NP or
osteocalcin were not measured at this time.
Bone densitometry showed severely low BMD at lumbar spine
(L-spine) 0.763 g/cm2 with a Z-score of −3.0, and at total right
hip 0.588 g/cm2 with a Z-score of −2.8. The TBS displayed also a
very low value, 1.16 compatible with highly degraded micro-
architecture. Pituitary MRI revealed a focal lesion in the sella turcica
consistent with microadenoma. The patient underwent trans-
phenoidal resection of the microadenoma.
One-year post-resection, AM cortisol and ACTH had normalized
(9.3 ug/dl and 21 pg/ml respectively). TBS improved to the normal
range (from 1.16 to 1.377, an 18.7% increase), and NTX returned to
normal. However, a repeat DXA obtained 8-months post-surgery showed
no signiﬁcant change in BMD at L-spine 0.753 g/cm2 (Z-score−3.1); a
15% improvement in BMD at the right total hip, 0.686 g/cm2 (Z-score
−2.3) (Figs. 1–2). The BMD remained severely low, and the patient was
started on Teriparatide (TPTD). During teriparatide therapy, patient's
bone speciﬁc alkaline phosphatase (BSAP) and bone resorptive NTX
appropriately increased, consistent with bone re-modeling and anabolic
formation, peaking at 59.1 (0–20 ug/L) and 367 BCE/mM (nl 3–51 nM
BCE/mM) respectively at 4 months of therapy.
After 2 years of TPTD, a repeat DXA revealed a 53.9% increase in BMD
at L-spine (1.154 g/cm2, Z-score 0.7); 50% increase at the total right hip
(0.977 g/cm2, Z-score−0.2) (Figs. 1–2). Trabecular bone score analysesFig. 1. DXA summary for changes in lumbar spine BMD from pre-operative to 5 years post-surg
TPTD for the next 2 years then one infusion with zoledronate.at the start of TPTD and at completion showed an 11.9% increase, less
than the change between surgery and the start of TPTD (18.7% increase)
and far less than the percent change in BMD after TPTD (Fig. 3). The
patient received an infusion of zoledronate upon completion of TPTD.
Repeat DXA 3 years later showed BMD that continued to improve at
spine and hip while the TBS remained stable as previously reported
after bisphosphonate (Silva et al., 2014).
Seven-years post-surgical cure, free cortisol and ACTH remained
normal 0.15 mcg/dl (nl 0.07–0.93 mcg/dl) and 27 (nl 6–50 pg/dl)
respectively. In addition, other pituitary hormones remained normal
with prolactin 5.6 ng/ml (nl 2–18 ng/ml), TSH 1.24 mIU/L (nl 0.4–
4.5 mIU/L) and LH 2 mIU/ml (1.5–9.3 mIU/ml).4. Discussion
Prior studies report a slow, progressive recovery of bonemass taking
up to 10 years in adolescents and adults “cured” of Cushing's disease (Di
Somma et al., 2003). In the current case, the patient's initial TBS of 1.16
met the criteria for having degradedmicroarchitecture of the trabecular
bone in the spine. TBS is classiﬁed into normal (N1.350); partially
degraded (1.2–1.35); and degraded microarchitecture (b1.2) (Silva
et al., 2014). This patient's degraded microarchitecture prior to surgery
is in agreement with the current literature, which demonstrated
progressive demineralization and degradation, primarily of trabecular
bone as a result of cortisol excess (Dalle Carbonare et al., 2005). Remark-
ably, the patient's TBS improved to normal range from 1.16 to 1.377
within 8 months post-surgical cure on calcium and vitamin D supple-
mentation alone.
While we cannot completely exclude the possibility that changes in
body composition in the marrow and visceral fat may have impacted
the TBS, several factors argue against that possibility. First, the TBS
was calculated using the updated TBS iNsight®-2.1 software, which
corrects for increased BMI and truncal adiposity in men (Leslie et al.,
2014). Second, the patient had BMI and abdominal thickness values
that did not signiﬁcantly change over the course of his illness and recov-
ery (Table 1). Third, in spite of the increase in abdominal thickness from
17 cm to 18.5 cm from start to completion of TPTD, which would beery: initially to 8 months post-surgery treatment with calcium and vitamin D alone, then
Fig. 2. DXA summary for changes in femoral neck BMD from pre-operative to 5 years post-surgery: initially to 8 months post-surgery treatment with calcium and vitamin D alone, then
TPTD for the next 2 years then one infusion with zoledronate.
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increase in TBS from 1.377 to 1.541.
Despite spontaneous normalization of TBS 8 months post-surgical
cure, BMD remained severely low. A clinical decision was made to
treat this presented patient with teriparatide for several reasons. First,
patient already suffered non-traumatic fragility fracture in setting of
very low BMD and also suffered from avascular necrosis of the hip.
Second, despite normalized cortisol and ACTH, patient's BMD remained
severely low 1-year post-surgical cure, which still placed the patient at
high risk for more fragility fractures. After 2 years of TPTD, patient's
BMD improved to normal Z-scores at the spine and femoral neck. This
is a signiﬁcantly more rapid correction of BMD compared to prior stud-
ies, which reported slow recovery of bone loss, taking up to 2–10 years
for complete recovery post-surgical cure (Di Somma et al., 2003).Fig. 3. Plotted percent changes in spinal BMD and TBS for the lumbar spine. TBS improved to no
was a slight decrease in bone density of−1.4%. After 2-years of teriparatide, bone density incre
rise slowly after zoledronate, no change was seen in the TBS.Although the improvement of BMD to normal range could have been
achieved eventually over time post-surgery for the described patient,
TPTD appears to have signiﬁcantly accelerated mineralization resulting
in complete normalization of BMD within two years.
It has previously been reported that the time and sequence of BMD
recovery in Cushing's patients post-surgery varies within the different
skeletal compartments. Earlier improvement was reported to occur at
the lumbar spine (mainly trabecular bone) and femoral neck (a mix of
trabecular and cortical bone) as compared to the whole body (80%
cortical bone) (Kristo et al., 2006), which is consistent with the ﬁndings
in the current study.
Further research is needed to better understand and identify the
mechanisms of bone repair in patients cured of Cushing's disease. One
can hypothesize that once the excess cortisol is removed by surgicalrmal range, with an 18.7% increase 8-months post-surgery. During this same period there
ased by 57.1% in the lumbar spine. TBS was further increased by 11.9%. BMD continued to
Table 1
Physical parameters, TBS and BMD during clinical course.
Date Weight
(kg)
BMI
(kg/m2)
Body
thickness (cm)*
TBS BMD
g/cm2
BMD % change from baseline
8/2007 (Pre-surgery) 73 24.3 20.4 1.16 0.863
9/2008 (8 months post-surgery) 69 24.1 17 1.377 0.753 −1.4%
12/2010 (Upon completion of TPTD for 2 years) 73 25 18.5 1.541 1.158 +57.1
1/2013 (25 months after ZOL) 77 26.2 19.5 1.525 1.253 +64.1%
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its function to normalize osteoblast function, increasing bone formation.
Furthermore, the increased caspase-3 activation from excess cortisol
will normalize, which will slow down osteocyte apoptosis (Rochefort
et al., 2010). However, it is still unclear how long it takes for the osteo-
blast to regain its function and its correlationwith clinical improvement
in bone strength, measured by BMD.
As presented in this case, the removal of excess cortisol allowed for
recovery of normal trabecular bone structure 8 months post-surgical
cure. However, the BMD remained very low, which improved to normal
after 2 years of teriparatide. Teriparatide, a recombinant parathyroid
hormone (PTH) works by providing intermittent exposure to PTH,
which is the primary regulator of calcium and phosphate metabolism
in bone and kidney. Intermittent exposure to teriparatide with once a
day injection results in activation of osteoblast more than osteoclast,
leading to net anabolic bone formation. In the presented case,
teriparatide likely accelerated normalization of BMD by increased acti-
vation of osteoblasts, which in turn mineralized the recovered trabecu-
lar bone architecture post-surgical cure.
On literature review, there are only two published case reports of
patients with Cushing's disease treated with TPTD. Both patients were
pre-menopausal women, treated for 24 and 6 months respectively,
and they showed a modest increase in LS BMD of 18% and 4.5% respec-
tively, far less impressive than the increase in BMD of 53.9% seen in our
case (Medina et al., 2013; Han et al., 2012). Both patients were started
on TPTD immediately after surgical resection without a waiting period
to assess spontaneous recovery of BMD. It is difﬁcult to determine
whether that 1-year delay in the treatment with teriparatide after the
surgical cure of Cushing's disease allowed for more rapid increase in
BMD with TPTD. However, the ﬁnding of complete recovery of TBS
post-surgical cure provides insight into the bone recovery process that
starts with trabecular bone repair, followed by mineralization, which
in this case likely was accelerated with TPTD.
To our knowledge, this is the ﬁrst case of TPTD use in a young male
patient with Cushing's induced osteoporosis that has successfully
normalized BMD after 2 years of therapy. It is also the ﬁrst case demon-
strating spontaneous recovery of TBS 8-months post-curative surgical
resection without pharmacologic therapy in a patient with Cushing's
disease. This ﬁnding provides more insight into the process and
sequence of bone repair in Cushing's disease post-surgery. Once the
endogenous excess cortisol is removed, the bone recovery seems to
startwith trabecular bone structure, as evidenced by rapid, spontaneous
normalization of TBS. The bone mineralization seems to begin once
trabecular structure has been restored. This ﬁnding may explain the
delayed improvement seen on DXA, which only measures mineraliza-
tion of the bone. Therefore, TBS measurement may be a helpful tool in
monitoring bone recovery in addition to DXA in patients with Cushing's
disease induced osteoporosis post-surgery.5. Conclusion
In Cushing's induced osteoporosis, a nearly complete restoration of
the TBS was seen within 8 months of curative surgery on calcium plus
vitamin D supplementation alone. Restoration of BMD was delayed and
most evident after trabecular microstructure repair, which can be accel-
erated on anabolic therapywith TPTD. The principle deﬁcits in trabecular
bone (i.e., trabecular microstructure and BMD) appeared to correct
quickly with time and treatment but in a discordant fashion. Therefore,
TBS measurement can be a helpful marker in monitoring bone recovery
in Cushing's patients post-surgery in addition to DXA to guide clinicians
in timing and choice of therapy such as bisphosphonates or teriparatide.
Acknowledgments
None.
Disclosure: S.K., O.D., and R.B. have nothing to disclose. D.H. is a co-
owner of the patent for TBS.
References
Canalis, E., Mazziotti, G., Giustina, A., Bilezikian, J.P., 2007. Glucocorticoid-induced
osteoporosis: pathophysiology and therapy. Osteoporos. Int. 18, 1319–1328.
Dalle Carbonare, L., Bertoldo, F., Valenti, M.T., Zenari, S., Zanatta, M., Sella, S., Giannini, S.,
Cascio, V.L., 2005. Histomorphometric analysis of glucocorticoid-induced osteoporo-
sis. Micron 36, 645–652.
Di Somma, C., Pivonello, R., Loche, S., Faggiano, A., Klain, M., Salvatore, M., Lombardi, G.,
Colao, A., 2003. Effect of 2 years of cortisol normalization on the impaired bone
mass and turnover in adolescent and adult patients with Cushing's disease: a
prospective study. Clin. Endocrinol. (Oxf.) 58, 302–308.
Han, J.Y., Lee, J., Kim, G.E., Yeo, J.Y., Kim, S.H., Nam, M., Kim, Y.S., Hong, S.B., 2012. A case of
Cushing syndrome diagnosed by recurrent pathologic fractures in a young woman.
J. Bone Metab. 19 (2), 153–158.
Hans, D., Barthe, N., Boutroy, S., Pothuaud, L., Winzenrieth, R., Krieg, M.A., 2011. Correla-
tions between trabecular bone score, measured using anteroposterior dual-energy
X-Ray absorptiometry acquisition, and 3-dimensional parameters of bone
microarchitecture: an experimental study on human cadaver vertebrae. J. Clin.
Densitom. 14 (3), 302–312 (Jul-Sep).
Hermus, A.R., Smals, A.G., Swinkels, L.M., Huysmans, D.A., Pieters, G.F., Sweep, C.F.,
Corstens, F.H., Kloppenborg, P.W., 1995. Bone mineral density and bone turnover
before and after surgical cure of Cushing's syndrome. J. Clin. Endocrinol. Metab. 80,
2859–2865.
Kristo, C., Jemtland, R., Ueland, T., Godang, K., Bollerslev, J., 2006. Restoration of the
coupling process and normalization of bone mass following successful treatment of
endogenous Cushing's syndrome: a prospective, long-term study. Eur. J. Endocrinol.
154, 109–118.
Leslie, W., Majumdar, S., Winzenrieth, R., Hans, D., Lix, L., 2014. Clinical Performance of an
Updated Version of Trabecular Bone Score in Men and Women: The Manitoba BMD
Cohort. Poster Presentation FR 0299, ASBMR 2014 in Houston, Tx.
Medina, G.S., Izquierdo, M.P., Curiel, D.M., 2013. Vertebral fractures as a debut to Cushing
syndrome diagnosed after a pregnancy. Rev. Osteoporos. Metab. Miner. 5 (2), 93–97.
Rochefort, G.Y., Phallu, S., Benhamou, C.L., 2010. Osteocyte: the unrecognized side of bone
tissue. Osteoporos. Int. 21, 1457–1469.
Silva, B.C., Leslie, W.D., Resch, H., Lamy, O., Lesnyak, O., Binkley, N., McCloskey, E.V., Kanis,
J.A., Bilezikian, J.P., 2014. Trabecular bone score: a noninvasive analytical method
based upon the DXA image. J. Bone Miner. Res. 29, 518–530.
